The Importance of Diversity in Eczema Clinical Trials

Eczema (especially atopic dermatitis) does not play favorites. It affects kids and adults of every race and ethnicity. Yet when you look at many eczema clinical trials, you still see a familiar pattern: study photos full of lighter skin tones and participant lists that don’t reflect the real-world population. That mismatch isn’t just a bad look for scienceit can lead to treatments that don’t work as well for everyone, or that miss important safety signals in underrepresented groups.

In recent years, researchers have documented significant racial and ethnic disparities in eczema prevalence, severity, diagnosis, and access to care. Black and Hispanic children in the United States, for example, are more likely to have severe eczema than white children and are less likely to see a doctor for it. At the same time, minorities remain underrepresented in many dermatology clinical trials, including those for atopic dermatitis.

So, let’s dig into why diversity in eczema clinical trials matters so much, how we got here, and what needs to changeideally with a bit of empathy, a dash of data, and only a sprinkle of gentle sarcasm toward outdated research habits.

Why Eczema Clinical Trials Need Diversity

Eczema Affects People of Color Disproportionately

Eczema is incredibly commonaffecting at least 10% of people at some point in lifebut it doesn’t strike all groups equally. In the U.S., Black children have higher rates of eczema than white children, and many studies suggest that eczema can be more persistent and more severe in patients with skin of color.

One large U.S. study found that eczema severity was associated with African American and Hispanic ethnicity, as well as lower household incomehighlighting the combined effect of biology, environment, and social determinants of health. Another analysis reported increasing eczema prevalence over time in Black, Hispanic, and multiracial children. In short: patients of color are carrying a heavy share of the eczema burden.

Clinical Trials Historically Skew Toward White Participants

Now look at who actually gets enrolled in trials. Across dermatology, including atopic dermatitis, racial and ethnic minority groups are often underrepresented compared with their prevalence in the general population. A recent analysis of atopic dermatitis clinical trials found that about two-thirds of participants identified as white, with much smaller proportions of Black, Hispanic, and Indigenous patientseven though people with skin of color experience significant eczema burden.

It’s a bit like testing a new sunscreen almost exclusively on people who never go outside, then being surprised when beachgoers get sunburned. If the trial participants don’t match the real-life patient population, the results may not tell the whole story.

What Happens When Diversity Is Missing?

1. We May Misjudge Treatment Effectiveness

Genetics, immune pathways, and environmental exposures can all influence how eczema develops and how patients respond to treatment. Some variants that affect skin barrier function and immune responses are more or less common in certain ethnic groups, which can change how well a medication works.

If a clinical trial includes very few patients with darker skin tones or from specific ethnic backgrounds, it becomes harder to know whether a promising drug will work equally well for themat the same dose, with the same benefit–risk balance. We might assume “one size fits all,” when in reality, we only tested “one size fits whoever showed up in the trial.”

2. We Can Overlook Safety Issues

Diversity in clinical trials isn’t just about how well drugs work; it’s also about how safe they are. Adverse events may be more or less common in different populations due to genetic factors, comorbid conditions, or even differences in metabolism and immune response.

If a trial doesn’t enroll enough patients from underrepresented groups, rare but serious side effects in those groups may not appear until after the drug is approved and widely used. That essentially turns everyday clinical practice into a “Phase 4 surprise,” which is not exactly the gold standard for patient safety.

3. We Miss How Eczema Looks on Different Skin Tones

Eczema on darker skin often doesn’t appear “red” in the textbook way. Instead, inflammation may show up as gray, purple, or deep brown patches; papular or follicular patterns; and long-lasting changes in pigmentation after flares.

When clinical trialsand the photos and scoring tools they useare built around lighter skin tones, clinical signs on darker skin may be underestimated or misinterpreted. That can lead to underestimating disease severity or overestimating how well a treatment is working. Representation in trials helps ensure that scoring systems, outcome measures, and physician training account for diverse skin tones.

4. We Reinforce Existing Health Disparities

Studies show that Black and Hispanic children with eczema are less likely to see a physician for the condition, despite having more severe disease. Structural barrierssuch as lower access to specialists, insurance gaps, or mistrust of the medical systemplay a big role. When those same groups are also underrepresented in trials, the medications that reach the market may be less tailored to their needs, further widening the gap in outcomes.

Diverse participation is one way to push back against these patterns: it brings the voices and experiences of patients with the greatest disease burden into the center of research, where decisions about therapies and guidelines are being made.

What’s Driving the Diversity Gap?

Historic and Ongoing Mistrust

For many communities of color, mistrust of clinical research and the broader medical system is not irrationalit’s historical. Past abuses in research, along with ongoing discrimination and inequitable care, understandably make people wary about signing up for a trial.

For eczema specifically, patients may already feel dismissed or misunderstood in routine care, especially when flares don’t look like textbook photos. Asking them to join a study run by a system that has not always served them well requires more than a glossy brochure; it requires transparency, partnership, and respect.

Practical Barriers to Participation

Even when patients want to participate, practical issues can get in the way:

• Location: Trials often take place at large academic centers, which may be far from where many patients of color live.
• Time and cost: Multiple visits, time off work, childcare, and transportation costs add up quickly.
• Awareness: Many people simply never hear that clinical trials exist or that they qualify for them.

Without targeted outreach and support, these barriers can quietly filter out those already facing the greatest eczema burden.

Trial Design and Recruitment Strategies

How trials are designed matters. Inclusion and exclusion criteria that inadvertently filter out common comorbidities in minority populations, recruitment strategies that rely mostly on existing patient lists at specialty clinics, and marketing materials that don’t reflect diverse communitiesall of these can reduce participation from underrepresented groups.

On the bright side, these are modifiable factors. Sponsors and researchers can rethink recruitment strategies, partner with community clinics, and develop trial designs that meet people where they are (literally and figuratively).

How Policy and Guidance Are Evolving

Regulators have started to push harder for diverse enrollment. The U.S. Food and Drug Administration (FDA) has issued guidance calling for reporting of race and ethnicity in clinical trials and for “Diversity Action Plans” to improve enrollment of underrepresented populations in certain studies.

Implementation, however, is still a work in progress. Recent political shifts have created uncertainty by temporarily removing some diversity guidance from public FDA web pages, even as federal law requires companies to outline strategies for enrolling diverse trial populations. Regardless of political swings, the scientific case for diversity remains strongespecially in conditions like eczema where disparities are well documented.

Strategies to Improve Diversity in Eczema Trials

1. Partner With Communities, Not Just Clinics

Successful eczema trials increasingly involve partnerships with community dermatology practices, primary care clinics, and patient advocacy groups that serve diverse populations. Organizations like the National Eczema Association, skin-of-color clinics, and community health centers can help build trust, share information, and provide feedback on trial design.

2. Make Participation Logistically Possible

Simple, practical changes can make a big difference:

• Offering evening or weekend visits
• Providing transportation support or travel stipends
• Offering childcare support or flexible scheduling
• Using telemedicine for some assessments

These steps signal that researchers understand participants’ real livesnot just their lab valuesand value their time.

3. Communicate Clearly and Culturally Competently

Recruitment materials should be written in plain language, translated where appropriate, and feature images of people with a range of skin tones and backgrounds. Staff should be trained in culturally competent communication and be prepared to discuss past research abuses honestly and respectfully.

4. Include Skin of Color Expertise in Study Teams

Dermatologists with expertise in skin of color and health disparities can help design more inclusive trials, interpret outcomes accurately, and ensure that scoring systems and photography capture eczema accurately across all skin tones.

5. Report and Analyze Data by Race, Ethnicity, and Skin Tone

It’s not enough to enroll diverse patientsyou have to analyze and report the results in a way that makes differences visible. That means prespecifying subgroup analyses, publishing racial/ethnic breakdowns, and being transparent about where data are still limited.

What This Means for Patients and Caregivers

For people living with eczema, diversity in clinical trials isn’t an abstract policy issueit’s about whether future treatments will work for you and people who look like you. When you see your community represented in studies, you can have more confidence that trial results, dosing recommendations, and safety information were built with your needs in mind.

Patients and caregivers who feel comfortable participating in eczema research can:

• Gain access to new treatments before they’re widely available
• Receive close monitoring from a research team
• Help generate data that improves care for their community

Of course, participation is always voluntary, and not everyone can or should join a trial. But having the optionand seeing that trials actively welcome diverse participantsis an important step toward equity.

Conclusion

Diversity in eczema clinical trials is not a “nice-to-have” feature or a box to tick to make a slide deck look better. It’s a scientific and ethical necessity. People with skin of color shoulder a disproportionate share of eczema’s burden, yet remain underrepresented in many trials that inform which treatments get approved and how they are used.

By prioritizing inclusive trial design, partnering with communities, addressing practical barriers, and rigorously analyzing outcomes across different racial and ethnic groups, the eczema research community can move toward treatments that are truly effective and safe for everyone. When clinical trials reflect the real world, patients don’t have to wonder whether the data apply to themthey can see themselves in the science.

SEO Summary & Metadata

sapo: Eczema hits people of all races and skin tones, but the clinical trials that shape treatment decisions haven’t always reflected that reality. When studies enroll mostly white participants, they can miss how eczema looks and behaves on darker skin, how social factors shape disease severity, and whether new medications work equally well across diverse communities. This article explores why diversity in eczema clinical trials is essentialfrom understanding genetic and environmental differences to capturing unique symptoms on skin of colorand offers practical strategies for making studies more inclusive, trustworthy, and patient centered.

Experiences and Perspectives: Why Diversity in Eczema Trials Feels Personal

Statistics and policy statements are important, but they don’t fully capture why diversity in eczema clinical trials feels so personal for many patients and families. To bring the issue to life, imagine a few everyday scenarios that echo what many people report in real-world care.

“It Didn’t Look Like the Pictures”

Picture a parent bringing their Black or brown child to a clinic because the child is scratching nonstop and waking up with bloody sheets. The parent has Googled “eczema” and seen page after page of photos on pale skinbright red patches, pink cheeks, obvious inflammation. Their child’s rash, meanwhile, looks more grayish-brown and bumpy, with areas of darker pigmentation where flares have come and gone. They worry that maybe it’s something else.

In the exam room, if the provider is trained mostly on lighter-skin images and trial data that rarely featured skin of color, they might underestimate severity or miss subtle signs. Families sometimes report being told to “just moisturize” or “wait it out,” even when sleep, school performance, and mental health are clearly being affected. When clinical trials include more patients with darker skinand publish high-quality images and scoring data from those participantsit helps shift training and expectations for what eczema “should” look like in everyone.

“I Didn’t Think Trials Were for People Like Me”

Another common experience is simply feeling invisible in research. Many adults with eczema, especially from historically marginalized communities, say they rarely see people who look like them in advertising for clinical trials or in educational materials. If all the recruitment images show fair-skinned participants, it can send a subtle message: this study isn’t designed with you in mind.

By contrast, when trial flyers, websites, and outreach events feature diverse faces and are offered in multiple languages, patients are more likely to feel that research is meant for them too. Community-based outreachsuch as partnering with local barbershops, churches, schools, or cultural organizationscan also change the narrative from “research happens somewhere far away to other people” to “this is something our community is actively shaping.”

“I’m Interested… But I Have a Life”

Even highly motivated patients can hit a wall when trial logistics are unrealistic. Think about a working parent with severe eczema who is juggling two jobs, kids’ schedules, and maybe an elderly relative. They might be excited about a new biologic or topical therapy being tested. But then they see the schedule: multiple weekday visits, hours in a waiting room, no support for transportation, and complicated paperwork written in dense medical jargon.

When trial designers ask for input from patients of different backgrounds before finalizing protocols, the study can be shaped around real life instead of an idealized calendar. That might mean offering evening visits, streamlining paperwork, or allowing some virtual check-ins. These kinds of accommodations are not just “nice extras”they are essential for ensuring that underrepresented groups can actually participate.

The Emotional Impact of Inclusion

For many people living with eczema, especially those who have felt dismissed or overlooked in healthcare settings, inclusive research sends an emotional message: “Your experience counts.” Knowing that scientists are actively trying to understand how eczema affects their communityand testing treatments with people who share their skin tone, cultural background, or living conditionscan boost trust and hope.

Conversely, when clinical trials repeatedly ignore the groups most affected by severe eczema, it can reinforce a sense of being an afterthought. Patients may feel that new therapies are “for other people,” and that their own flares, scars, and sleepless nights are not driving innovation. Changing that narrative requires both diverse enrollment and transparent communication about who is represented in study results.

How Patients and Families Can Get Involved Safely

If you or your child live with eczema and are curious about research, it can help to:

• Ask your dermatologist whether any eczema trials are available that match your situation.
• Visit reputable trial listing sites (for example, large academic centers or national organizations) and search for “eczema” or “atopic dermatitis.”
• Bring questions about risks, benefits, time commitments, and compensation to any screening visit.
• Consider whether the research team seems transparent, respectful, and responsive to your concerns.

Saying “no” is always okay. But having the chance to say “yes” to well-designed, inclusive studiesand seeing people like you actively recruitedcan be empowering.

Looking Ahead

The push for diversity in eczema clinical trials is still a work in progress, but the direction is clear. Researchers, regulators, clinicians, and patient advocates increasingly agree that trials must reflect the real-world population if we want treatments that truly work for everyone. That means centering the experiences of communities that have historically been left out of research, not as an afterthought, but as a core part of study design.

Ultimately, the importance of diversity in eczema clinical trials comes down to a simple idea: people with eczema should see themselvesin all their skin tones, backgrounds, and life circumstancesin the science that shapes their care. When that happens, the promise of personalized, equitable treatment for eczema comes much closer to reality.